Cantoni Therapeutics
Pre-clinicalCantoni Therapeutics is dedicated to the discovery and development of best-in-class small molecule inhibitors towards nicotinamide N-methyltransferase (NNMT), a novel and promising target for cardiometabolic disease and other indications
Founded
2021
Focus
Small Molecules
About
Cantoni Therapeutics is dedicated to the discovery and development of best-in-class small molecule inhibitors towards nicotinamide N-methyltransferase (NNMT), a novel and promising target for cardiometabolic disease and other indications
Funding History
1Total raised: $3.5M
Seed$3.5MBioGeneration VenturesMar 15, 2022
Company Info
TypePrivate
Founded2021
LocationAmsterdam, Netherlands
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
2-BBB Medicines
Pre-clinical · Leiden
Batavia Biosciences
Pre-clinical · Leiden
Bilthoven Biologicals
Pre-clinical · Bilthoven
Agendia
Pre-clinical · Amsterdam
Alloksys Life Sciences
Phase 2 · Wageningen
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile